logo
Twitter
Discord
Email
logo
Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

NASDAQ•TNDM
CEO: Mr. John F. Sheridan
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2013-11-14
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Contact Information
12400 High Bluff Drive, San Diego, CA, 92130, United States
858-366-6900
www.tandemdiabetes.com
Market Cap
$1.50B
P/E (TTM)
-7.3
32.2
Dividend Yield
--
52W High
$38.28
52W Low
$9.98
52W Range
43%
Rank66Top 89.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$249.25M-31.39%
4-Quarter Trend

EPS

-$0.31-11.43%
4-Quarter Trend

FCF

$4.17M-80.63%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Q3 Sales Increased Marginally Total sales reached $249.3M for the quarter ended September 30, 2025, showing growth over $244.0M reported in 2024.
Gross Margin Significantly Expanded Gross margin improved to 54% for the three months ended September 30, 2025, up from 51% in the prior year period.
Operating and Net Losses Narrowed Net loss decreased to ($21.2M) in Q3 2025 from ($23.3M) in Q3 2024, driven by better gross profit performance.
Cash Position Remains Strong Cash and cash equivalents totaled $91.9M at September 30, 2025, supporting liquidity for at least the next 12 months.

Risk Factors

Major Non-Operating Expenses Recorded Nine months results impacted by $75.2M IPR&D charge related to AMF acquisition and $20.0M litigation expense.
Reimbursement Coverage Uncertainty Failure to secure or retain adequate coverage from third-party payors, including CMS changes, could severely limit future product sales.
Competitive Product Obsolescence Risk Breakthroughs by competitors or changes in diabetes treatment may render current pump technology obsolete or reduce market size.
Supply Chain Dependency Risks Reliance on limited third-party suppliers for components creates risk of delays, quality issues, and inability to meet demand.

Outlook

Future Technology Pipeline Active Pipeline includes next-generation patch pump (next Tandem Mobi) and dual glucose-ketone sensor integration efforts underway.
Shifting to Pharmacy Sales Channel Implementing multi-channel strategy offering pumps and supplies via pharmacy benefit for broader customer access and flexibility.
Liquidity Sufficient for 12 Months Management believes current cash ($319.1M total short-term resources) is sufficient to fund ongoing core business activities for 12 months.
Managing Operating Expense Growth Expenses expected to increase due to commercial expansion, R&D investments, and facility footprint growth, requiring careful management.

Peer Comparison

Revenue (TTM)

Evolent Health, Inc.EVH
$2.05B
-16.6%
Integra LifeSciences Holdings CorporationIART
$1.64B
+5.0%
Tandem Diabetes Care, Inc.TNDM
$1.01B
+3.4%

Gross Margin (Latest Quarter)

Xencor, Inc.XNCR
93.9%
+11.7pp
Tango Therapeutics, Inc.TNGX
80.4%
-16.5pp
InMode Ltd.INMD
80.0%
-0.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TNDM$1.50B-7.3-118.8%51.4%
IRMD$1.24B59.823.3%0.0%
PCRX$1.20B39.23.9%0.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-4.1%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-$0.06
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $249.25M-31.4%
    |
    EPS: $-0.31-11.4%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $240.68M+8.5%
    |
    EPS: $-0.78+66.0%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 30, 2025|
    Revenue: $234.42M+22.3%
    |
    EPS: $-1.97+203.1%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $940.20M+25.7%
    |
    EPS: $-1.47+57.1%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $363.29M+95.7%
    |
    EPS: $-0.35-31.4%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $221.91M+13.3%
    |
    EPS: $-0.47-14.5%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $191.67M+13.2%
    |
    EPS: $-0.65-66.1%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $747.72M-6.7%
    |
    EPS: $-3.43-133.3%
    Miss